A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Running, not enrolling · Phase 1

Conditions studied: Multiple Myeloma

In brief

The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optimal dose(s) of elranatamab plus maplirpacept. All study medicines are given over 4-week cycles. Everyone taking part in this study will receive elranatamab as a shot under the skin. Participants in Part 1 will also receive weekly carfilzomib as an IV infusion (given directly into a vein) and dexamethasone either by mouth (as a pill) or by IV infusion. Participants in Part 2 will receive elranatamab in combination with maplirpacept as an IV infusion (given directly into a vein) The investigators will examine the experiences of people receiving the study medicines. This will help determine if the study medicines are safe and can be used for multiple myeloma treatment. Participants will take part in this study for about 2 years after the first dose.

Key facts

Study ID

NCT05675449

Run by

Pfizer

People needed

59

Starts

2022-12-14

Expected to finish

2028-02-29

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Prior diagnosis of multiple myeloma as defined by IMWG criteria.
• Measurable disease based on IMWG criteria as defined by at least 1 of the following:
• Serum M-protein ≥0.5 g/dL.
• Urinary M-protein excretion ≥200 mg/24 hours.
• Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio (<0.26 or >1.65).
• Part 1: Received at least 1 but not more than 3 prior lines of therapy for multiple myeloma (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy).
• Part 2: Received at least 3 prior lines of therapy for multiple myeloma who are refractory to at least one IMiD, one PI and one anti-CD38 antibody.
• ECOG performance status 0-1.
• Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.
• Not pregnant or breastfeeding and willing to use contraception.

You may not qualify if…

• Plasma cell leukemia, Smouldering MM, Waldenströms macroglobulinemia, Amyloidosis, POEMS Syndrome, Primary refractory MM
• Impaired cardiovascular function or clinically significant cardiovascular diseases.
• Participants with any active, uncontrolled bacterial, fungal, or viral infection.
• Stem cell transplant within 12 weeks prior to enrollment, or active graft versus host disease.
• Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
• Part 1: Previous treatment with a BCMA-directed therapy.
• Part 2: Previous treatment with any anti-BCMA directed therapy, with the exception of CAR-T. Previous treatment with a CD47-SIRP alpha-directed therapy.
• Part 1: Prior treatment with carfilzomib
• Live attenuated vaccine within 4 weeks of the first dose of study intervention.
• Administration with an investigational product (e.g. drug or vaccine) concurrent with study intervention or within 30 days preceding the first dose of study intervention used in this study.
• Any of the following within 3 months of enrollment: erosive esophagitis, treatment resistant peptic ulcer, infectious or inflammatory bowel disease, pulmonary embolism or uncontrolled thromboembolic event.
• Intolerance to or participants who have had a severe (Grade ≥3) allergic or anaphylactic reaction to antibodies or therapeutic proteins

Where it is running

• Dana Farber/Mass General Brigham Cancer Care, Inc — Boston, Massachusetts, United States
• MSK Monmouth — Middletown, New Jersey, United States
• Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). — New York, New York, United States
• Memorial Sloan Kettering Cancer Center - Main Campus — New York, New York, United States
• Henry-Joyce Cancer Clinic — Nashville, Tennessee, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Rambam Health Care Campus — Haifa, Israel
• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• Beverly Hills Cancer Center — Beverly Hills, California, United States
• Clinical Research Advisors (Encino Satellite Location) — Encino, California, United States
• Clinical Research Advisors (Korea Town Satellite Location) — Los Angeles, California, United States
• Clinical Research Advisors (West Hollywood Satellite Location) — Los Angeles, California, United States
• Sylvester Comprehensive Cancer Center - Aventura — Aventura, Florida, United States
• Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center — Coral Gables, Florida, United States
• Sylvester Comprehensive Cancer Center - Coral Springs — Coral Springs, Florida, United States
• University of Miami Hospital and Clinics - Deerfield Beach — Deerfield Beach, Florida, United States
• Sylvester Comprehensive Cancer Center - Hollywood — Hollywood, Florida, United States
• Griffin Cancer Research Building (GCRB) — Miami, Florida, United States
• Sylvester Comprehensive Cancer Center — Miami, Florida, United States
• University of Miami Hospital and Clinics — Miami, Florida, United States
• Sylvester Comprehensive Cancer Center - Kendall — Miami, Florida, United States
• Sylvester Comprehensive Cancer Center - Plantation — Plantation, Florida, United States
• Emory University Hospital Midtown — Atlanta, Georgia, United States
• Emory University Administration Office — Atlanta, Georgia, United States
• Emory University Hospital — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.